192 related articles for article (PubMed ID: 36399647)
21. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
[TBL] [Abstract][Full Text] [Related]
22. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
[TBL] [Abstract][Full Text] [Related]
23. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.
Xu Y; Chen C; Guo Y; Hu S; Sun Z
Front Immunol; 2022; 13():848327. PubMed ID: 35300341
[TBL] [Abstract][Full Text] [Related]
24. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
25. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
26. Lipid-, Inorganic-, Polymer-, and DNA-Based Nanocarriers for Delivery of the CRISPR/Cas9 system.
Song N; Chu Y; Tang J; Yang D
Chembiochem; 2023 Aug; 24(16):e202300180. PubMed ID: 37183575
[TBL] [Abstract][Full Text] [Related]
27. Editing the immune system in vivo in mice using CRISPR/Cas9 ribonucleoprotein (RNP)-mediated gene editing of transplanted hematopoietic stem cells.
Wang R; Graham S; Gao L; Tam J; Levesque MC
Methods; 2021 Oct; 194():30-36. PubMed ID: 33422676
[TBL] [Abstract][Full Text] [Related]
28. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
29. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
30. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
31. Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades").
Mangeot PE; Guiguettaz L; Sohier TJM; Ricci EP
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33871447
[TBL] [Abstract][Full Text] [Related]
32. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
33. Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer.
Li Y; Li C; Yan J; Liao Y; Qin C; Wang L; Huang Y; Yang C; Wang J; Ding X; Yang YY; Yuan P
Biomaterials; 2024 Sep; 309():122573. PubMed ID: 38677222
[TBL] [Abstract][Full Text] [Related]
34. A quaternary ammonium-based nanosystem enables delivery of CRISPR/Cas9 for cancer therapy.
Zhang M; Sun S; Liang X; Liu Z; Yin J; Li Q; Yang S
Biomater Sci; 2024 Feb; 12(5):1197-1210. PubMed ID: 38240497
[TBL] [Abstract][Full Text] [Related]
35. Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples.
Eerkens AL; Vledder A; van Rooij N; Foijer F; Nijman HW; de Bruyn M
Immunol Cell Biol; 2022 Apr; 100(4):285-295. PubMed ID: 35194830
[TBL] [Abstract][Full Text] [Related]
36. Optimisation of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 : single-guide RNA (sgRNA) delivery system in a goat model.
Huang Y; Ding Y; Liu Y; Zhou S; Ding Q; Yan H; Ma B; Zhao X; Wang X; Chen Y
Reprod Fertil Dev; 2019 Aug; 31(9):1533-1537. PubMed ID: 31079595
[TBL] [Abstract][Full Text] [Related]
37. Genome editing using preassembled CRISPR-Cas9 ribonucleoprotein complexes in Fusarium graminearum.
Lee N; Park J; Kim JE; Shin JY; Min K; Son H
PLoS One; 2022; 17(6):e0268855. PubMed ID: 35657788
[TBL] [Abstract][Full Text] [Related]
38. Biologically produced and metal-organic framework delivered dual-cut CRISPR/Cas9 system for efficient gene editing and sensitized cancer therapy.
Yu J; Tang M; Zhou Z; Wei Z; Wan F; Hou S; Li Q; Li Y; Tian L
Acta Biomater; 2024 Apr; 178():296-306. PubMed ID: 38417646
[TBL] [Abstract][Full Text] [Related]
39. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
[TBL] [Abstract][Full Text] [Related]
40. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
